Mariella D'adda

Brescia, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 51 publications

Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact (D-IMPACT) Project.

Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact (D-IMPACT) Project.

Journal: Cancers
Published: April 08, 2026

Second attempt to discontinue TKI after molecular relapse in patients with chronic myeloid leukemia: A real-life Italian multicenter study.

Second attempt to discontinue TKI after molecular relapse in patients with chronic myeloid leukemia: A real-life Italian multicenter study.

Journal: Cancer
Published: November 16, 2025

ET occurring in NPM1-mutated AML during molecular complete remission: A further potential evolution of a complex disease.

ET occurring in NPM1-mutated AML during molecular complete remission: A further potential evolution of a complex disease.

Journal: British journal of haematology
Published: March 26, 2025

Therapeutic Vaccinations with p210 Peptides in Imatinib-Treated Chronic Myeloid Leukemia Patients: 10 Years Follow-Up of GIMEMA CML0206 and SI0207 Studies.

Therapeutic Vaccinations with p210 Peptides in Imatinib-Treated Chronic Myeloid Leukemia Patients: 10 Years Follow-Up of GIMEMA CML0206 and SI0207 Studies.

Journal: Vaccines
Published: March 10, 2025

The 2024 Three-Strata Baseline Anemia Definition of the Revised IWG-ELN Criteria Dissects Survival in Ruxolitinib-Treated Myelofibrosis Patients.

The 2024 Three-Strata Baseline Anemia Definition of the Revised IWG-ELN Criteria Dissects Survival in Ruxolitinib-Treated Myelofibrosis Patients.

Journal: American journal of hematology
Published: March 05, 2025

Bone Marrow CD34+/lin- Cells of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) After 12 Months of Nilotinib Treatment Exhibit a Different Gene Expression Signature Compared to the Diagnosis and the Corresponding Cells from Healthy Subjects.

Bone Marrow CD34+/lin- Cells of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) After 12 Months of Nilotinib Treatment Exhibit a Different Gene Expression Signature Compared to the Diagnosis and the Corresponding Cells from Healthy Subjects.

Journal: Cancers
Published: February 13, 2025

Direct determination of chronic myeloid leukemia prevalence in Lombardy-Italy: Global implications.

Direct determination of chronic myeloid leukemia prevalence in Lombardy-Italy: Global implications.

Journal: Hematological oncology
Published: August 09, 2024

Potential role of the spleen in the development of arterial hypertension in humans.

Potential role of the spleen in the development of arterial hypertension in humans.

Journal: Journal of hypertension
Published: May 11, 2024

Bosutinib Treatment of Chronic Myeloid Leukemia in Lombardy.

Bosutinib Treatment of Chronic Myeloid Leukemia in Lombardy.

Journal: Acta haematologica
Published: April 28, 2024

Italian Physicians' Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA Survey.

Italian Physicians' Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA Survey.

Journal: Journal of clinical medicine
Published: July 18, 2023

Prednisone vs high-dose dexamethasone in newly diagnosed adult primary immune thrombocytopenia: a randomized trial.

Prednisone vs high-dose dexamethasone in newly diagnosed adult primary immune thrombocytopenia: a randomized trial.

Journal: Blood advances
Published: June 20, 2023

Accessory spleens recapitulate the immune microenvironment of the main spleen in immune thrombocytopenia.

Accessory spleens recapitulate the immune microenvironment of the main spleen in immune thrombocytopenia.

Journal: British journal of haematology
Published: December 23, 2022
Showing 1-12 of 51

Last Updated: 09/26/2026